Suppressing chondrocyte cuproptosis by syringaresinol-4-O-β-d-glucoside alleviates gouty arthritis
SSG can serve as a promising therapeutic option for gouty arthritis in clinical settings by suppressing inflammation and preserving cartilage integrity.
Authors
- Han Du (ORCID: https://orcid.org/0000-0002-3174-6935)
- Peixiang Ma (ORCID: https://orcid.org/0000-0001-6794-1663)
- Wugui Chen
- Ling Xiao (ORCID: https://orcid.org/0000-0002-2576-2963)
- Chengzhao Liu
- An Qin (ORCID: https://orcid.org/0000-0002-8785-8848)
- Chengshou Lin
- Hailong Ma (ORCID: https://orcid.org/0000-0001-9577-3126)
- Hang Zhang (ORCID: https://orcid.org/0000-0002-0590-9593)
- Jianan Chen (ORCID: https://orcid.org/0000-0002-6673-6884)
- HanYi Wang (ORCID: https://orcid.org/0000-0002-7528-8817)
- Shaotian Fu
Institutions
- Fujian Medical University (CN)
- Shanghai Ninth People's Hospital (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-05-09
- DOI
- https://doi.org/10.3389/fphar.2025.1565422
- Citations
- 5
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 7.15
Funders
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province